Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Combining hypomethylating agents in AML

Amer Zeidan • 1 Jun 2020
ASCO 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Decitabine

Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, discusses studies presented at ASCO 2020 investigating hypomethylating agent combination therapy for acute myeloid leukemia treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Amer Zeidan

1:52
Advances in LR-MDS and HR-MDS in 2023 and beyond
Amer Zeidan • 9 Dec 2023
2:14
Trial updates for luspatercept in LR-MDS: COMMANDS, MEDALIST and ELEMENTS-MDS
Amer Zeidan • 9 Dec 2023
1:45
Real-world data: oral decitabine plus cedazuridine versus IV/SC hypomethylating agents
Amer Zeidan • 9 Dec 2023
2:21
STIMULUS-MDS1: sabatolimab + HMAs in untreated HR-MDS
Amer Zeidan • 9 Dec 2023

Related Videos

2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals